A correlation of Apo AI turnover with survival and response to first line platinum-based chemotherapy in advanced NSCLC was confirmed, and normalization of Apo AI was associated with a low risk of progression of cancer [48]. This evidence concerns the gene APOA1 and non-small cell lung carcinoma.